- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Roche Joins the Immuno-oncology Front With a PD-L1 inhibitor
While the current approved immuno-oncolgy drugs have been approved for melanoma, Roche has also been evaluating their new molecule in triple-negative breast cancer. The results will be presented at the San Antonio Breast Cancer Symposium.
Swiss drugmaker Roche is to present data on its experimental immunotherapy drug in breast cancer next month, extending the novel approach to fighting tumours to another cancer type.
Early clinical results with the drug, known as MPDL3280A, in so-called triple negative breast cancer will be revealed at the Dec. 9-13 San Antonio Breast Cancer Symposium, the company said on Thursday after announcing third-quarter results.
The Roche product belongs to a drug class known as anti-PD-L1 treatments that help the body's immune system fend off cancer by blocking a protein used by tumours to evade disease-fighting cells.
Developed first for melanoma, these medicines are also showing promise in a range of other tumour types.
Report on Reuters: http://reut.rs/1FbqH9z
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
